Developer docs
API playgroundTry for free, no card

Search company profiles

Complix

Full company profile

uuid0003cfu

Namestring
Complix
Legal namestring
Complix N.V.
Websiteurl
complix.com
Company typeenum
Private
Founded yearint
2008
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDiepenbeek, Belgium
HQ citystring
Diepenbeek
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell penetrating alphabodies, intracellular biotherapeutics, protein therapeutics, drug discovery platform, undruggable targets
Industry1 code
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Drug Discovery and Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Partnership Milestone Payments
TypeLicensing Royalties
Description

Complix receives upfront payments and potential development and regulatory milestone payments from pharmaceutical partners. The MSD collaboration is worth up to $280 million in upfront and milestone payments, plus tiered mid-single digit royalties on global sales.

complix.com
2Research Funding
TypeProfessional Services
Description

Partners such as MSD fund research activities related to CPAB development programs.

complix.com
3Royalty Payments
TypeLicensing Royalties
Description

Complix is eligible to receive tiered royalties based on future commercial sales of developed therapeutics in licensed territories.

complix.com
4Grant Funding
TypeLicensing Royalties
Description

Complix receives government grants for research programs, such as the €1.2 million VLAIO grant for anti-Covid-19 Alphabody development and €0.5 million VLAIO grant for nuclear targeting CPABs.

complix.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Alphabody
Description

Complix's proprietary platform technology for developing transformative biotherapeutics that can penetrate cells and address intracellular targets.

complix.com
+2 more records
Core offering1 text field

Complix develops Cell Penetrating Alphabodies (CPABs), a proprietary class of biopharmaceuticals that combine the specificity of antibodies with the cell-penetrating capacity of small molecules. The company's pipeline targets intracellular disease mediators — primarily in oncology, immuno-oncology, autoimmune disease, CNS disease, and viral infections — that are considered intractable by conventional antibody or small-molecule drug formats. CPABs are licensed and co-developed with major pharmaceutical partners through upfront payments, milestone payments, and royalties.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CPABs can remain stable within tumor tissue for up to 24 hours post administration
+2 more records
Product overview1 text field

Complix is a biopharmaceutical company built around its proprietary Alphabody platform, which generates Cell Penetrating Alphabodies (CPABs) — a novel class of biotherapeutics that combine the high specificity of antibodies with the cell-penetrating ability of small molecules. The platform enables access to intracellular targets in the cytosol and nucleus that are considered 'undruggable' by conventional drug formats. The company's pipeline includes CMX-02 (a bispecific Alphabody-antibody fusion targeting TNFα and IL-23 for autoimmune disease), anti-MCL-1 CPABs for oncology, and Covid-19 Alphabody therapeutics. Complix is also engaged in partnered programs with MSD (Merck), I-Mab, and Jiangsu Nhwa for oncology, immuno-oncology, and CNS disease applications.

Product and service8 records
1Cell Penetrating Alphabodies (CPABs) Platform
CategoryBiotherapeutic Platform
Description

Proprietary class of biotherapeutics combining the specificity of antibodies with the cell-penetrating capacity of small molecules; enables access to intracellular targets in the cytosol and nucleus that are considered undruggable by conventional drug formats. Offered to pharmaceutical partners through licensing and co-development.

2CMX-02 (Bispecific TNFα/IL-23 Alphabody-Antibody Fusion)
CategoryPipeline Therapeutic Candidate (Autoimmune)
Description

Bispecific Alphabody-antibody fusion protein that simultaneously targets TNFα and IL-23 cytokines for the treatment of severe autoimmune diseases (e.g., psoriatic arthritis, Crohn's disease). Being developed using the Selexis SUREtechnology Platform for manufacturing.

3Anti-MCL-1 CPABs
CategoryPipeline Therapeutic Candidate (Oncology)
Description

Cell Penetrating Alphabodies targeting the intracellular cancer target MCL-1, an apoptosis regulator implicated in multiple hematological cancers; part of Complix's oncology pipeline developed under the MSD collaboration.

4CMX-01 (Oncology CPAB Therapeutic)
CategoryPipeline Therapeutic Candidate (Oncology)
Description

Cell Penetrating Alphabody therapeutic candidate targeting intracellular oncogenic drivers for cancer treatment under the MSD collaboration.

5Anti-Coronavirus Alphabody Therapeutics
CategoryPipeline Therapeutic Candidate (Antiviral)
Description

Anti-coronavirus Alphabody therapeutics targeting highly conserved viral fusion machinery for both prophylactic and therapeutic efficacy against SARS-CoV-2 and future coronavirus variants.

6MSD Cancer CPAB Collaboration (Up to $280M)
CategoryStrategic Partnership / Licensing Agreement
Description

Strategic co-development and licensing agreement with MSD worth up to US$280M for the development of CPABs against intracellular cancer targets; MSD funds research and holds option to exclusive worldwide rights.

7I-Mab Immuno-Oncology CPAB Collaboration
CategoryStrategic Partnership / Licensing Agreement
Description

Global drug discovery agreement with I-Mab to develop CPABs against two intracellular immuno-oncology targets. Complix retains joint development and commercialization rights outside Greater China; I-Mab holds exclusive Greater China commercialization rights.

8Jiangsu Nhwa CNS Disease CPAB Collaboration
CategoryStrategic Partnership / Licensing Agreement
Description

Global collaboration with Jiangsu Nhwa Pharmaceutical Co. to develop CPABs that cross the blood-brain barrier for CNS diseases; exclusive Greater China license to Nhwa, with joint development and commercialization rights for the rest of the world.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-28
Description

Global collaboration and license agreement to develop CPABs able to cross the blood-brain barrier for CNS diseases. Complix granted exclusive license to Nhwa for Greater China development, manufacturing, and commercialization. Both companies retain joint development and commercialization rights for rest of world. Complix entitled to upfront license payments, milestone payments, and royalty payments on commercial sales in China.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-31
Description

Joint multidisciplinary research collaboration with VIB and Ghent University resulting in publication in Science Advances. Study demonstrates CPABs efficiently penetrate cancer cell membranes, disrupt intracellular protein-protein interfaces, and cause anti-tumor effects in vivo. Prof Savvas Savvides leads VIB team at Center for Inflammation Research.

3I-Mab
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-10
Description

Global drug discovery and development agreement for CPABs against two intracellular immuno-oncology targets. Complix retains joint development and commercialization rights outside Greater China. I-Mab has exclusive license to commercialize in Greater China. Complix receives upfront fees, research funding, and potential milestone and royalty payments.

complix.com
4Prof Savvas Savvides (VIB-UGent Center for Inflammation Research)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-10-07
Description

Research collaboration on anti-viral Alphabody program focusing on 3D-structure determination of Alphabody-viral protein complexes.

complix.com
5Prof Johan Neyts (Rega Institute for Medical Research, KU Leuven)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-10-07
Description

Research collaboration on anti-viral Alphabody program for functional characterization of anti-viral compounds.

complix.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-12-01
Description

Strategic drug discovery collaboration to develop Cell Penetrating Alphabodies for cancer treatment. Complix uses its Alphabody platform to deliver CPABs against up to two intracellular cancer targets. MSD funds research and has option to exclusive worldwide rights. Complix entitled to upfront payment and potential development milestones up to $280 million plus tiered royalties. Collaboration expanded in July 2017 when MSD exercised option on second target program.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Foghorn develops medicines that target chromatin regulatory machinery, including previously undruggable intracellular cancer targets. Its focus on intracellular oncology biology overlaps with Complix's intracellular cancer target thesis, particularly around transcription factors and regulatory proteins.

TypeEmerging player
Description

Harpoon develops engineered T-cell engagers (TriTACs) and other targeted protein-based immunotherapies for oncology. It shares Complix's approach of using proprietary protein engineering to address cancer targets with novel binding modalities.

TypeEmerging player
Description

CytomX's Probody platform engineers conditionally activated antibody therapeutics, including for intracellular targets via masking strategies. It overlaps with Complix in the pursuit of protein-based therapeutics aimed at challenging oncology targets beyond conventional antibody reach.

TypeEmerging player
Description

Arvinas is the pioneer of PROTAC targeted protein degraders, leveraging bifunctional small molecules to address intracellular disease-driving proteins. Like Complix, Arvinas pursues intracellular oncology targets that have historically been considered undruggable.

TypeDirect peer
Description

Bicycle Therapeutics develops bicyclic peptides, a constrained peptide scaffold similar in concept to Complix's alpha-helical Alphabodies, with the goal of addressing intracellular and traditionally hard-to-drug targets in oncology. Both companies use small, computationally designed protein/peptide scaffolds to reach targets outside the reach of conventional antibodies.

TypeEmerging player
Description

Crinetics develops oral peptide therapeutics targeting G-protein-coupled receptors and other challenging endocrine and oncology targets. It shares Complix's emphasis on non-injectable routes of administration and tackling disease targets that conventional biologics cannot reach.

TypeEmerging player
Description

Nurix develops targeted protein degradation drugs (PROTACs and molecular glues) that hijack the cell's ubiquitin-proteasome system to eliminate disease-driving proteins, including intracellular targets such as transcription factors. Like Complix, Nurix pursues intracellular oncology targets that conventional drugs cannot address.

TypeBroad incumbent
Description

Regeneron operates one of the largest protein-based therapeutic platforms, including antibody and bispecific approaches addressing oncology and autoimmune disease. It is comparable to Complix as a benchmark for how protein-engineering platforms can scale into multi-billion-dollar franchises.

TypeBroad incumbent
Description

Ablynx (acquired by Sanofi) pioneered Nanobodies, small single-domain antibody fragments, and was co-founded by Complix CEO Mark Vaeck. It represents the broader small-protein-therapeutic precedent most directly relevant to Complix's Alphabody platform and serves as a benchmark for the asset class's commercial potential.

TypeDirect peer
Description

Affibody develops small protein scaffolds (affibody molecules) for therapeutic applications including oncology and autoimmune disease. Like Complix's Alphabodies, affibody molecules are rationally designed, small protein-based binders intended to access targets that traditional antibodies struggle to address.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Complix

Biopharmaceutical Drug Discovery and Developmentcomplix.com

Complix firmographics

Firmographics
Name
Complix
Legal name
Complix N.V.
Website
https://complix.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Complix industry classification

Industry
Product category
Biopharmaceutical Drug Discovery and Development
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Cell penetrating alphabodies
  • Intracellular biotherapeutics
  • Protein therapeutics
  • Drug discovery platform
  • Undruggable targets

Where Complix is headquartered

Location

Headquarters

HQ city
Diepenbeek
HQ country
Belgium
HQ region
Europe

Offices3 records

Markets served

Complix business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Partnership Milestone Payments: Complix receives upfront payments and potential development and regulatory milestone payments from pharmaceutical partners. The MSD collaboration is worth up to $280 million in upfront and milestone payments, plus tiered mid-single digit royalties on global sales.
  2. Research Funding: Partners such as MSD fund research activities related to CPAB development programs.
  3. Royalty Payments: Complix is eligible to receive tiered royalties based on future commercial sales of developed therapeutics in licensed territories.
  4. Grant Funding: Complix receives government grants for research programs, such as the €1.2 million VLAIO grant for anti-Covid-19 Alphabody development and €0.5 million VLAIO grant for nuclear targeting CPABs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Complix product offering

Product offering

Core offering

Complix develops Cell Penetrating Alphabodies (CPABs), a proprietary class of biopharmaceuticals that combine the specificity of antibodies with the cell-penetrating capacity of small molecules. The company's pipeline targets intracellular disease mediators — primarily in oncology, immuno-oncology, autoimmune disease, CNS disease, and viral infections — that are considered intractable by conventional antibody or small-molecule drug formats. CPABs are licensed and co-developed with major pharmaceutical partners through upfront payments, milestone payments, and royalties.

Product overview

Complix is a biopharmaceutical company built around its proprietary Alphabody platform, which generates Cell Penetrating Alphabodies (CPABs) — a novel class of biotherapeutics that combine the high specificity of antibodies with the cell-penetrating ability of small molecules. The platform enables access to intracellular targets in the cytosol and nucleus that are considered 'undruggable' by conventional drug formats. The company's pipeline includes CMX-02 (a bispecific Alphabody-antibody fusion targeting TNFα and IL-23 for autoimmune disease), anti-MCL-1 CPABs for oncology, and Covid-19 Alphabody therapeutics. Complix is also engaged in partnered programs with MSD (Merck), I-Mab, and Jiangsu Nhwa for oncology, immuno-oncology, and CNS disease applications.

Differentiator

Problem solved

Functional benefit

Brands

  • Alphabody: Complix's proprietary platform technology for developing transformative biotherapeutics that can penetrate cells and address intracellular targets.
  • Cell Penetrating Alphabodies (CPAB)
  • CMX-02

Products and services

  • Cell Penetrating Alphabodies (CPABs) Platform Proprietary class of biotherapeutics combining the specificity of antibodies with the cell-penetrating capacity of small molecules; enables access to intracellular targets in the cytosol and nucleus that are considered undruggable by conventional drug formats. Offered to pharmaceutical partners through licensing and co-development.
  • CMX-02 (Bispecific TNFα/IL-23 Alphabody-Antibody Fusion) Bispecific Alphabody-antibody fusion protein that simultaneously targets TNFα and IL-23 cytokines for the treatment of severe autoimmune diseases (e.g., psoriatic arthritis, Crohn's disease). Being developed using the Selexis SUREtechnology Platform for manufacturing.
  • Anti-MCL-1 CPABs Cell Penetrating Alphabodies targeting the intracellular cancer target MCL-1, an apoptosis regulator implicated in multiple hematological cancers; part of Complix's oncology pipeline developed under the MSD collaboration.
  • CMX-01 (Oncology CPAB Therapeutic) Cell Penetrating Alphabody therapeutic candidate targeting intracellular oncogenic drivers for cancer treatment under the MSD collaboration.
  • Anti-Coronavirus Alphabody Therapeutics Anti-coronavirus Alphabody therapeutics targeting highly conserved viral fusion machinery for both prophylactic and therapeutic efficacy against SARS-CoV-2 and future coronavirus variants.
  • MSD Cancer CPAB Collaboration (Up to $280M) Strategic co-development and licensing agreement with MSD worth up to US$280M for the development of CPABs against intracellular cancer targets; MSD funds research and holds option to exclusive worldwide rights.
  • I-Mab Immuno-Oncology CPAB Collaboration Global drug discovery agreement with I-Mab to develop CPABs against two intracellular immuno-oncology targets. Complix retains joint development and commercialization rights outside Greater China; I-Mab holds exclusive Greater China commercialization rights.
  • Jiangsu Nhwa CNS Disease CPAB Collaboration Global collaboration with Jiangsu Nhwa Pharmaceutical Co. to develop CPABs that cross the blood-brain barrier for CNS diseases; exclusive Greater China license to Nhwa, with joint development and commercialization rights for the rest of the world.

Quantifiable outcome

  • CPABs can remain stable within tumor tissue for up to 24 hours post administration
  • +2 more outcomes

Companies that use Complix

Customer profile

Segments5 records

Ideal customer profiles1 record

Complix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Complix partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Jiangsu Nhwa Pharmaceutical Co.coreStrategic or Co-development Partner · 28 July 2021Global collaboration and license agreement to develop CPABs able to cross the blood-brain barrier for CNS diseases. Complix granted exclusive license to Nhwa for Greater China development, manufacturing, and commercialization. Both companies retain joint development and commercialization rights for rest of world. Complix entitled to upfront license payments, milestone payments, and royalty payments on commercial sales in China.
  • VIB (Vlaams Instituut voor Biotechnologie)coreStrategic or Co-development Partner · 31 March 2021Joint multidisciplinary research collaboration with VIB and Ghent University resulting in publication in Science Advances. Study demonstrates CPABs efficiently penetrate cancer cell membranes, disrupt intracellular protein-protein interfaces, and cause anti-tumor effects in vivo. Prof Savvas Savvides leads VIB team at Center for Inflammation Research.
  • I-MabcoreStrategic or Co-development Partner · 10 March 2021Global drug discovery and development agreement for CPABs against two intracellular immuno-oncology targets. Complix retains joint development and commercialization rights outside Greater China. I-Mab has exclusive license to commercialize in Greater China. Complix receives upfront fees, research funding, and potential milestone and royalty payments.
  • Prof Savvas Savvides (VIB-UGent Center for Inflammation Research)minorStrategic or Co-development Partner · 7 October 2020Research collaboration on anti-viral Alphabody program focusing on 3D-structure determination of Alphabody-viral protein complexes.
  • Prof Johan Neyts (Rega Institute for Medical Research, KU Leuven)minorStrategic or Co-development Partner · 7 October 2020Research collaboration on anti-viral Alphabody program for functional characterization of anti-viral compounds.
  • MSD (Merck & Co., Inc.)coreStrategic or Co-development Partner · 1 December 2015Strategic drug discovery collaboration to develop Cell Penetrating Alphabodies for cancer treatment. Complix uses its Alphabody platform to deliver CPABs against up to two intracellular cancer targets. MSD funds research and has option to exclusive worldwide rights. Complix entitled to upfront payment and potential development milestones up to $280 million plus tiered royalties. Collaboration expanded in July 2017 when MSD exercised option on second target program.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Complix competitors and assessment

Company assessment

Emerging players

  • Foghorn Therapeutics: Foghorn develops medicines that target chromatin regulatory machinery, including previously undruggable intracellular cancer targets. Its focus on intracellular oncology biology overlaps with Complix's intracellular cancer target thesis, particularly around transcription factors and regulatory proteins.
  • Harpoon Therapeutics: Harpoon develops engineered T-cell engagers (TriTACs) and other targeted protein-based immunotherapies for oncology. It shares Complix's approach of using proprietary protein engineering to address cancer targets with novel binding modalities.
  • CytomX Therapeutics: CytomX's Probody platform engineers conditionally activated antibody therapeutics, including for intracellular targets via masking strategies. It overlaps with Complix in the pursuit of protein-based therapeutics aimed at challenging oncology targets beyond conventional antibody reach.
  • Arvinas: Arvinas is the pioneer of PROTAC targeted protein degraders, leveraging bifunctional small molecules to address intracellular disease-driving proteins. Like Complix, Arvinas pursues intracellular oncology targets that have historically been considered undruggable.
  • Crinetics Pharmaceuticals: Crinetics develops oral peptide therapeutics targeting G-protein-coupled receptors and other challenging endocrine and oncology targets. It shares Complix's emphasis on non-injectable routes of administration and tackling disease targets that conventional biologics cannot reach.
  • Nurix Therapeutics: Nurix develops targeted protein degradation drugs (PROTACs and molecular glues) that hijack the cell's ubiquitin-proteasome system to eliminate disease-driving proteins, including intracellular targets such as transcription factors. Like Complix, Nurix pursues intracellular oncology targets that conventional drugs cannot address.

Direct peers

  • Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptides, a constrained peptide scaffold similar in concept to Complix's alpha-helical Alphabodies, with the goal of addressing intracellular and traditionally hard-to-drug targets in oncology. Both companies use small, computationally designed protein/peptide scaffolds to reach targets outside the reach of conventional antibodies.
  • Affibody: Affibody develops small protein scaffolds (affibody molecules) for therapeutic applications including oncology and autoimmune disease. Like Complix's Alphabodies, affibody molecules are rationally designed, small protein-based binders intended to access targets that traditional antibodies struggle to address.

Broad incumbents

  • Regeneron Pharmaceuticals: Regeneron operates one of the largest protein-based therapeutic platforms, including antibody and bispecific approaches addressing oncology and autoimmune disease. It is comparable to Complix as a benchmark for how protein-engineering platforms can scale into multi-billion-dollar franchises.
  • Ablynx (Sanofi): Ablynx (acquired by Sanofi) pioneered Nanobodies, small single-domain antibody fragments, and was co-founded by Complix CEO Mark Vaeck. It represents the broader small-protein-therapeutic precedent most directly relevant to Complix's Alphabody platform and serves as a benchmark for the asset class's commercial potential.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Complix social profiles

Digital presence

Complix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Complix leadership team

Management profile

Number of profiles

Profiles6 records

Complix subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Complix funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Complix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Complix

What does Complix do?

Complix develops Cell Penetrating Alphabodies (CPABs), a proprietary class of biopharmaceuticals that combine the specificity of antibodies with the cell-penetrating capacity of small molecules. The company's pipeline targets intracellular disease mediators — primarily in oncology, immuno-oncology, autoimmune disease, CNS disease, and viral infections — that are considered intractable by conventional antibody or small-molecule drug formats. CPABs are licensed and co-developed with major pharmaceutical partners through upfront payments, milestone payments, and royalties.

Is Complix a public or private company?

Complix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Complix founded?

Complix was founded in 2008. It employs 1 to 10 people.

Where is Complix based?

Complix is headquartered in Diepenbeek, Belgium, in the Europe region.

How does Complix make money?

Four revenue lines are on record. Partnership Milestone Payments are the primary driver. The others are research Funding, royalty Payments and grant Funding.

Who are Complix's main competitors?

Emerging players on record are Foghorn Therapeutics, Harpoon Therapeutics, CytomX Therapeutics, Arvinas, Crinetics Pharmaceuticals and Nurix Therapeutics. Direct peers are Bicycle Therapeutics and Affibody. Broad incumbents are Regeneron Pharmaceuticals and Ablynx (Sanofi).

Does Complix have an API?

No public API is recorded for Complix.

What industry is Complix in?

Complix's product category is Biopharmaceutical Drug Discovery and Development. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireComplix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS DiseasesComplix has signed a global collaboration and license agreement with Jiangsu Nhwa Pharmaceutical Co. to develop Cell Penetrating Alphabodies (CPABs) for the treatment of central nervous system diseases. Under the deal, Complix grants an exclusive license to Nhwa for development, manufacturing, and commercialization in Greater China, while both companies retain joint rights for the rest of the world. The partnership leverages Complix's proprietary technology to create therapeutics that can cross the blood-brain barrier.PR NewswireComplix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science AdvancesComplix, a biopharmaceutical company, in collaboration with Belgian research institute VIB and Ghent University, published proof-of-concept research in Science Advances demonstrating that Cell-Penetrating Alphabodies (CPABs) can efficiently penetrate cancer cell membranes, disrupt intracellular protein-protein interactions, and produce anti-tumor effects in animal models. The study targeted MCL-1, a protein upregulated in multiple tumor types and correlated with therapy resistance, representing what researchers describe as a unique combination of cell penetration, intracellular targeting, and half-life extension in a single protein scaffold. The findings provide validation for CPABs as a novel therapeutic platform potentially applicable to oncology and other intracellular disease targets previously considered "intractable" by conventional biologics and small molecules.PR NewswireComplix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology TargetsComplix, a Belgian biopharmaceutical company, has signed a global drug discovery and development agreement with I-Mab (Nasdaq: IMAB) to develop Cell Penetrating Alphabodies (CPABs) against two intracellular immuno-oncology targets using Complix's proprietary Alphabody platform. Under the terms of the agreement, I-Mab receives exclusive commercialization rights for Greater China while both companies share equal rights to the rest of the world, with Complix entitled to an upfront payment, potential development milestones, and tiered royalties. The partnership aims to advance novel CPAB therapeutics capable of addressing intracellular targets that are considered intractable by current drug formats such as antibodies or small chemicals.PrwebOMPLIX Launches New Trading Platform, Offers Competitive Rates on Tens of TokensOMPLIX launched a new trading platform offering access to tens of cryptocurrency tokens with competitive rates. The platform includes large-cap assets like Bitcoin and Ether, as well as altcoins such as IOTA, Tron, and Tezos. OMPLIX plans to continuously upgrade its offer to stay aligned with market trends.FinSMEsComplix Receives €0.5M GrantComplix, a Belgian biopharmaceutical company, received a €0.5M grant from the Flemish Agency for Innovation & Entrepreneurship. The funds will support development of its Cell Penetrating Alphabody platform targeting intracellular cancer cell nuclei. The company has raised over €27M since 2008 and has a collaboration with Merck.PR NewswireComplix Receives €0.5 Million Grant to Further Develop its Pipeline of Proprietary Cell Penetrating Alphabodies™ Against Intracellular Cancer TargetsComplix has been awarded a €0.5 million grant from the Flemish Agency for Innovation & Entrepreneurship (VLAIO) to further develop its proprietary Cell Penetrating Alphabodies (CPABs) against intracellular cancer targets. This funding supports research into CPABs that can penetrate the nucleus of cancer cells to modulate regulatory proteins essential for cancer growth. The company also maintains a strategic collaboration with Merck & Co for the development of novel therapeutics based on this platform.PR NewswireComplix Announces Expanded Strategic Oncology Collaboration with MSD to Develop Cell-Penetrating AlphabodiesComplix, a Belgian biopharmaceutical company, announced that MSD (Merck & Co., Inc.) has exercised its option for a second cancer target program under their strategic collaboration initiated in December 2015. MSD is funding the research and holds exclusive worldwide rights to resulting candidates, triggering an option fee payment to Complix. The collaboration is worth up to $280 million in upfront and development milestones plus tiered royalties, with Complix's CEO calling the decision a strong validation of their Alphabody platform technology.PR NewswireComplix Enters into Strategic Collaboration with MSD to Develop Cell-Penetrating Alphabodies to Treat CancerComplix, a Belgian biopharmaceutical company, has entered into a strategic drug discovery collaboration with MSD (Merck & Co., Inc.) to develop Cell-Penetrating Alphabodies for cancer treatment, using Complix's proprietary Alphabody platform against up to two intracellular cancer targets. MSD will fund the research and has an option for exclusive worldwide rights to any resulting compounds, with Complix entitled to receive an upfront payment and potential development milestones of up to $280 million, plus tiered royalties. The collaboration represents a validation of Complix's CPAB technology, which has demonstrated the ability to enter tumor cells and selectively modulate intracellular protein-to-protein interactions considered difficult to target with current therapies.PR NewswireComplix Appoints Hans Schikan as ChairmanComplix appointed Hans Schikan as Chairman of its Board of Directors on July 29, 2015. Schikan previously served as CEO of Prosensa, which was acquired by BioMarin for up to $840 million. He will contribute to expanding Complix's Alphabody pipeline for cancer and autoimmune diseases.FinSMEsComplix Raises €5M in Series A Equity FinancingComplix NV raised €5M in Series A equity financing co-led by Vesalius Biocapital and LRM. The capital will fund development of therapeutic products based on its Alphabody platform, targeting autoimmunity and infectious diseases.